Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Monzr M. Al Malki, Yi-Bin Chen, Tania Jain, Alla Keyzner, Melhem Solh, Uday Popat, Michele Donato, Luis Pineiro, Hugo Fernandez, Saar Gill, Anson Snow, Joseph Uberti, Sameem Abedin, Mahasweta Gooptu, Mathew Angelos, Jeremy Pantin, Kwang Woo Ahn, Ramola Bhandarkar, Shrikanta Chattopadhyay, Samantha Jaglowski, Chrystal Louis, Michelle Matzko, Leavitt Morrison, Waleska Pérez, Eugene Poggio, Ran Reshef
Institutions: City Of Hope National Medical Center, Harvard University, Massachusetts General Hospital, Johns Hopkins University, Tisch Cancer Institute, Northside Hospital, The University of Texas MD Anderson Cancer Center, Hackensack University Medical Center, Baylor College of Medicine, Hospital of the University of Pennsylvania, Abramson Cancer Center, University of North Carolina at Chapel Hill, The Barbara Ann Karmanos Cancer Institute, Medical College of Wisconsin, Medical College of Wisconsin Cancer Center, Dana-Farber Cancer Institute, Sarah Cannon, TScan Therapeutics (United States), Biostatistical Consulting (United States), Columbia University Irving Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108790669
Cites:
Cited by:
Related to: